A previous study of the clinical response of PD1 to the treatment of tumors, melanoma, renal-cell cancer, and non–small-cell lung cancer presented a pronounced objective response, whereas no objective responses were observed in patients with prostate cancer or CC [67]. This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.